Clinical Trial Update: Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-positive Adults [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and immunogenicity of GlaxoSmithKline's TB vaccine candidate Mtb72F/AS02A in healthy PPD-positive adults; the study has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• Mtb72F/AS02A vaccine (Mtb72F/AS02A)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Tuberculosis (TB) | Phase 2 | Status: COMPLETED